Iovance Biotherapeutics, Inc.
Biotechnology ResearchView the employees at
Iovance Biotherapeutics, Inc.-
Aneesah Maloney Quality Operations Specialist II at Iovance Biopharmaceuticals
-
Rising Star
Jackie Holcomb (Suzuki) VP of Finance, Corporate Controller at Iovance Biotherapeutics, Inc.-
Rising Star
Maria Corredera-Bachenski Sr. Recruiter at Iovance Biotherapeutics/Sr. Relationship Management-
Top 5%
Jaqulyn Gamble Aseptic Pharmacy Technician with 4 years of experience working in various Laboratory settings using equipment. Working hands-on with animals, insects, rodents, and exotic wildlife combined for 6 years of practice.-
Maple Shade, New Jersey, United States
-
Rising Star
Allison Marotta Associate Director, Supply Chain at Iovance Biotherapeutics, Inc.-
Philadelphia
-
Rising Star
Overview
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we actively prepare for our initial commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings
-